Prostate Cell News

Prostate Cell News is an online resource summarizing the latest prostate cell research.

Johnson & Johnson Reports 75% Tumor Response Rate in Advanced Prostate Cancer with JNJ-6143, a First-in-Class RIPTAC™ Molecule

October 30, 2026

[Johnson & Johnson] Johnson & Johnson announced Phase I results for JNJ-6143, an investigational once-daily oral Regulated Induced Proximity Targeting Chimera small molecule, in patients with advanced prostate cancer who had received multiple prior treatments. Among patients with measurable disease, 75% had a confirmed complete or partial response.

Syncromune® Reports Long-Term Data from Phase I Study in Metastatic Prostate Cancer with Investigational SYNC-T Therapy SV-102

October 30, 2026

[Syncromune, Inc.] Syncromune, Inc. announced updated overall survival results from a Phase I trial of its investigational SYNC-T Therapy SV-102 in patients with metastatic prostate cancer.

Pfizer’s TALZENNA Plus XTANDI FDA-Approved for an Earlier Metastatic Prostate Cancer Treatment Setting

October 30, 2026

[Pfizer, Inc.] Pfizer, Inc. announced that the US FDA has expanded approval of TALZENNA^® (talazoparib) in combination with XTANDI^® (enzalutamide) to the treatment of men with metastatic androgen pathway modulation-naïve or -sensitive prostate cancer with homologous recombination repair gene mutations.

Hyperoside Promotes Ferroptosis in Prostate Cancer by Modulation of Tryptophan Metabolism via Flotillin-2 Reduction

October 30, 2026

[European Journal of Pharmacology] Scientists proposed that hyperoside (HYP) exerts its anti-prostate cancer activity by inducing ferroptosis via flotillin-2 (FLOT2) downregulation. Mechanistically, HYP interacts with FLOT2, suppresses STAT3-mediated indoleamine 2,3-dioxygenase 1 expression, thereby blocking tryptophan metabolism and interrupting kynurenine-aryl hydrocarbon receptor signaling.

Dual Neuromodulation Remodels Neuro-Immune Crosstalk and Chemokine Network for Combating Postoperative Progression of Prostate Cancer

October 30, 2026

[Advanced Materials] Paired proteomic profiling of specimens from ten patients identified VCPIP1 as a candidate regulator, and its clinical relevance was evaluated in an independent cohort of 128 metastatic hormone-sensitive prostate cancer patients.

The VCPIP1-UBE3A Deubiquitination-Ubiquitination Cascade Contributes to Castration-Resistant Prostate Cancer Progression

October 30, 2026

[Advanced Science] Paired proteomic profiling of specimens from ten patients identified VCPIP1 as a candidate regulator, and its clinical relevance was evaluated in an independent cohort of 128 metastatic hormone sensitive patients.

Genetically Reprogrammed Exosomes for Targeted Prostate Cancer Immunotherapy

October 30, 2026

[Acta Biomaterialia] Researchers exploited a genetic approach to display both anti-human prostate-specific membrane antigen and anti-human CD3 antibodies on exosomal surface. Through simultaneously targeting T cells and prostate cancer tumors, the resulting prostate cancer immunotherapeutic exosomes were designed to induce robust anti-cancer cellular immunity.

Opposing Roles of Acid Phosphatase 1 (ACP1) and ACP3 in Prostate Cancer Progression

October 30, 2026

[BJU International] The authors conducted a systemic review and meta-analysis to assess the associations between intracellular acid phosphatase 1 (ACP1) and ACP3 expression and clinical outcomes, including disease presence, Gleason grade, tumor stage, lymph node involvement, and patient survival in prostate cancer.

Transferrin Functionalization Enhances Prostate Cancer Cell Uptake and Cytotoxicity of Cabazitaxel-Loaded Polymeric Nanoparticles

October 30, 2026

[International Journal of Pharmaceutics] Investigators encapsulated abazitaxel in polycaprolactone polymeric nanoparticles functionalized with transferrin, and evaluated its in vitro activity in prostate cancer cell lines.

Four Million Euros in EU Funding to Improve Prostate Cancer Care

October 16, 2026

[German Cancer Research Center] The European Commission is funding the “PROMETHEUS” consortium project with a total of four million euros over four years, of which 1.6 million euros will be allocated to the German Cancer Research Center.

Vir Biotechnology Announces PSMA-targeted PRO-XTEN® Dual-masked T-cell Engager VIR-5500 Received FDA Fast Track Designation for the Treatment of Prostate Cancer

October 16, 2026

[Vir Biotechnology, Inc.] Vir Biotechnology, Inc. announced that the US FDA granted Fast Track designation to VIR-5500, a PSMA-targeted PRO-XTEN® dual-masked T-cell engager, for the treatment of late-line metastatic CRPC.

Prostate Cancer Foundation Honors Mary-Ellen Taplin, MD, with the 2026 PCF Women in Science Lifetime Achievement Award

October 16, 2026

[Prostate Cancer Foundation] The Prostate Cancer Foundation announced Mary-Ellen Taplin, MD, as the recipient of the 2026 PCF Women in Science Lifetime Achievement Award.

Published since 2010, Prostate Cell News compiles top scientific journal articles covering the characterization, behavior, and culturing of prostate cells. Additionally, our editorial team curates the latest press releases, technical advances, jobs, and events relevant to the prostate cell research community. Prostate Cell News saves scientists valuable time while keeping them informed in their field, facilitating the rapid exchange of cutting edge research updates and science news.